Eculizumab to Prevent Antibody-mediated Rejection in ABO Blood Group Incompatible Living Donor Kidney Transplantation
Status:
Terminated
Trial end date:
2014-04-01
Target enrollment:
Participant gender:
Summary
The purpose of this study is to try to determine if the drug eculizumab can help prevent
antibody-mediated rejection in patients undergoing a kidney transplant from a living donor
with a different blood type than their own.